Scientists studying the effects of so-called booster vaccines say the body’s T-cell immune response, after the third stab, can protect against hospitalization and death.
CovBoost Research – published in Fingertips – also seems to legitimize the UK’s decision to primarily supply Pfizer-BioNTech or Moderna as the third injection, with mRNA stabs leading to the most significant increase in immunoreactivity levels.
Health Minister Sajid Javid announced on wednesday that the government purchased an additional 114 million doses of these two vaccines, following advice from the Joint Committee on Immunization and Immunization (JCVI) to put them at the top of the list.
However, Professor Saul Faust, trial leader and director of the NIHR Clinical Research Facility at University Hospital Southampton NHS Foundation Trust, said researchers had found that AstraZeneca, Novavax and Janssen were all a safe and effective booster dose for people already taking Pfizer or AstraZeneca – like most people in the UK.
Are not Vaccine According to the study, raised any safety concerns, with fatigue, headaches and arm pain being the most commonly reported problems, which Professor Faust described as “really encouraging.” “.
“That gives confidence and flexibility in developing programs that ramp up in the UK and globally, given other factors such as supply chain and logistics,” he said. added that the drills performed well against existing variants, such as delta, but that omicron was not tested in the study.
It is thought that T-cell immunity, studied in the trial alongside antibodies, could play a ‘critical role’ in combating the new variant – discovered for the first time in southern Africa . The cells play an important role and work together with antibodies in the immune system to target the virus.
Professor Faust said of this development: “Although we do not properly understand its association with long-term immunity, the T-cell data tell us that it appears to be broader for With all variants, this gives us hope that the variant strain of the virus can be tackled, inevitably with hospitalization and death if not prevented, with vaccines. -please present”.
When asked specifically about omicrons, Professor Faust added: “Our hope as scientists is that the ability to protect against hospitalization and death will remain intact.”
When looking at antibody levels in the trial, people who received the initial two doses of AstraZeneca had a 1.8- to 32.3-fold higher boosted response, depending on the booster vaccine used.
After two doses of Pfizer, this range was 1.3 times to 11.5 times higher, with the study’s authors warning these ratios should be interpreted “with caution” as they are not associated with protection. in the real world against disease.
Samples from the CovBoost trial, which included 2,878 people aged 30 years and over who received a booster shot 10 to 12 weeks after the initial two doses, have now been turned over to the UK Health Security Agency (UKHSA) for review. consider the level of omicron neutralization. by vaccine.
Jonathan Ball, professor of molecular virology at the University of Nottingham, hailed the “wonderful study” as a “fantastic [way] to finally see the data that is certainly pivotal in deciding on the UK’s approach to vaccine booster”.
Professor Ball told the PA news agency: “The fact that booster vaccine mRNA has markedly increased both antibodies and T cells is great news, especially now that the emergence of omicron variation is attracted by the appearance of omicron variation.
The researchers note that additional data from the trial will be published next year, including statistics on immunity and whether a longer time interval between the second and third doses of the vaccine could be beneficial. improve response or not.
Speaking after receiving his strengthen jab on Thursday, Boris Johnson again instructing the British public to refrain from canceling Christmas plans in the face of omicrons, saying it was “unnecessary”.
“The most important thing you can do in any case is use the booster when you are called on,” Prime Minister told Sky News. “We’ve done 18.6 million booster shots in this country, so we’re building the wall of defense higher and higher.”
“Whatever the omicron can or may not do, it certainly won’t negate the overall value of the booster,” he added.
Additional report of PA
https://www.independent.co.uk/news/health/covid-booster-vaccines-uk-study-b1968948.html Study shows that Covid-boosted vaccine can provide good protection against new variants